Citigroup’s CNS Pharmaceuticals CNSP Stock Holding History

Citigroup’s Portfolio CNSP Stock Details CNSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$2	–	5796
2026 Q1	$2	Buy	+1	New	+$4	﹤0.01%	5825
2025 Q4	–	Sell	-2	Closed	-$18	–	6124
2025 Q3	$18	Buy	+2	New	+$16	﹤0.01%	5908
2022 Q3	–	Hold	0	–	-$4K	–	5887
2022 Q2	–	Hold	0	–	–	–	5668

Other funds holding CNSP

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return

Citigroup's CNSP Position: Q2 2026 in Review

Citigroup sold out of CNS Pharmaceuticals (CNSP) in Q2 2026, closing a stake of 1 share — an estimated $2 sold.

Citigroup first reported a position in CNSP in Q3 2025 and held it in 2 quarters. The position peaked at $18 in Q3 2025. 11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

Citigroup reported no remaining CNS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Citigroup sold 1 CNS Pharmaceuticals share in Q2 2026, an estimated $2.
Citigroup first reported a position in CNS Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Citigroup's CNS Pharmaceuticals position peaked at $18 in Q3 2025.
11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.